Drug Trial Radar · NCT07912359
Effect of Synbiotic Therapy on Renal Function Outcomes in Patients With Chronic Kidney Disease Stage III-IV: A Double-blind Randomized Placebo-controlled Trial.
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
96
Planned (sponsor's estimate)
Start
Oct 11, 2026
Primary completion
Nov 11, 2027
Study completion Jan 11, 2028
Sponsor
- Lead sponsor
- Chittagong Medical CollegeAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 3, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Background: Chronic kidney disease (CKD) represents a growing global public health challenge, with rising prevalence in low and middle-income countries, including Bangladesh. Progressive renal dysfunction is frequently accompanied by gut microbiota alterations, leading to increased intestinal permeability and systemic inflammation through the gut-kidney axis. Accumulation of uremic toxins derived from dysbiotic microbiota has been implicated in CKD progression. Synbiotic therapy, combining probiotics and prebiotics, has been proposed as a strategy to restore microbial balance and reduce inflammatory burden. Objective: To evaluate effect of Synbiotic Therapy on Renal Function Outcomes in Patients with Chronic Kidney Disease Stage III-IV. Materials and Methods: This Double-blind, randomized placebo-controlled trial will be conducted in the Department of Nephrology, Chittagong Medical College Hospital, Bangladesh. Approximately 96 adult non-dialysis CKD stage III-IV patients will be enrolled. Participants will be randomly allocated into two arms of treatment. The experimental arm and the control arm. Both arm with receive standard care according to KDIGO recommendations. The experimental arm will receive synbiotic therapy and the control arm with receive placebo in addition to standard therapy. Clinical and laboratory assessments will be performed at baseline, after 1.5 months and after 3 months. Outcome measures are change in S. Creatinine, e-GFR, Blood Urea Nitrogen (BUN), C-Reactive protein (CRP), and Gastrointestinal symptom dynamics using Gastrointestinal System Rating Scale (GSRS). Data Analysis Plan: An intention-to-treat or per protocol approach will be applied as applicable. Parametric or non-parametric tests will be applied as appropriate. Repeated-measures analysis will assess longitudinal changes. Conclusion: The expected findings may clarify the potential role of gut microbiota modulation as an adjunct in CKD management in Bangladesh and similar settings and may inform future multicenter trials.
Conditions
- Chronic Kidney Disease (Stage 3-4)
Interventions
Experimental arm will get synbiotic therapy containing Lactobacillus acidophilus (15 billion CFU), Bifidobacterium longum (15 billion CFU), Streptococcus thermophilus(15 billion CFU), along with xyloDrug
This intervention includes comparatively large sample size
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Serum Creatinine From Baseline to 3 MonthsTime frame: One year and six months(11th June 2026 to 11th December 2027)
- Change in Estimated Glomerular Filtration Rate (eGFR) From Baseline to 3 MonthsTime frame: One year and six months(11th June 2026 to 11th December 2027)
- Change in Blood Urea Nitrogen (BUN) From Baseline to 3 MonthsTime frame: One year and six months(11th June 2026 to 11th December 2027)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Chittagong Medical College and Hospital
Chittagong, Bangladesh · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.